Iguacel Isabel, Maldonado Aurelio Luna, Ruiz-Cabello Aurelio Luna, Casaus Marta, Moreno Luis Alberto, Martínez-Jarreta Begoña
Faculty of Health Sciences, University of Zaragoza, 50009 Zaragoza, Spain.
Instituto Agroalimentario de Aragón, 50013 Zaragoza, Spain.
Vaccines (Basel). 2021 Nov 15;9(11):1321. doi: 10.3390/vaccines9111321.
COVID-19 vaccines have shown high efficacy, with most side effects being mild-moderate and more frequently reported by females and people at younger ages. Since no studies have assessed the impact that weight status could have on the reported adverse reactions, we aim to study the association between weight status and reported side effects. We included data on 2136 adults from an online survey conducted from 6 May to 9 June 2021. The questionnaire was filled in by participants over Google forms. Generalized Linear Mixed Models were used. A higher risk of presenting fever ≥38°, vomiting, diarrhea and chills was found in those with a non-overweight status compared to those overweight after adjusting for age, sex, education, medication to prevent/relieve post-vaccination effects and vaccine administered. When adjusting, most of the significant effects, in the association between side effects of the COVID-19 vaccine and weight status, did not remain significant. In conclusion, a non-overweight status was associated with a higher risk of presenting fever ≥38°, vomiting, diarrhea and chills compared to those overweight. Nevertheless, most of the reported side effects to COVID-19 vaccine were not associated with a higher risk of presenting more adverse effects, and individual differences were determined by sex and age.
新冠疫苗已显示出高效性，大多数副作用为轻至中度，且女性和年轻人报告的频率更高。由于尚无研究评估体重状况对报告的不良反应可能产生的影响，我们旨在研究体重状况与报告的副作用之间的关联。我们纳入了2021年5月6日至6月9日进行的一项在线调查中2136名成年人的数据。问卷由参与者通过谷歌表单填写。使用了广义线性混合模型。在调整年龄、性别、教育程度、预防/缓解疫苗接种后效应的药物以及接种的疫苗后，发现与超重者相比，体重正常者出现≥38°发热、呕吐、腹泻和寒战的风险更高。在调整时，新冠疫苗副作用与体重状况之间关联中的大多数显著效应不再显著。总之，与超重者相比，体重正常者出现≥38°发热、呕吐、腹泻和寒战的风险更高。然而，报告的大多数新冠疫苗副作用与出现更多不良反应的较高风险无关，个体差异由性别和年龄决定。
